Leap Therapeutics Past Earnings Performance
Past criteria checks 0/6
Leap Therapeutics's earnings have been declining at an average annual rate of -23.6%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been declining at an average rate of 10.9% per year.
Key information
-23.6%
Earnings growth rate
28.5%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -10.9% |
| Return on equity | -112.7% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Leap Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -53 | 14 | 45 |
| 31 Dec 23 | 0 | -81 | 14 | 72 |
| 30 Sep 23 | 0 | -81 | 14 | 71 |
| 30 Jun 23 | 0 | -82 | 13 | 71 |
| 31 Mar 23 | 0 | -86 | 13 | 74 |
| 31 Dec 22 | 0 | -55 | 12 | 43 |
| 30 Sep 22 | 0 | -53 | 12 | 41 |
| 30 Jun 22 | 1 | -49 | 11 | 38 |
| 31 Mar 22 | 1 | -42 | 11 | 32 |
| 31 Dec 21 | 2 | -41 | 11 | 31 |
| 30 Sep 21 | 2 | -37 | 10 | 28 |
| 30 Jun 21 | 2 | -32 | 10 | 24 |
| 31 Mar 21 | 2 | -29 | 10 | 22 |
| 31 Dec 20 | 2 | -38 | 10 | 20 |
| 30 Sep 20 | 1 | -39 | 10 | 21 |
| 30 Jun 20 | 1 | -40 | 9 | 21 |
| 31 Mar 20 | 0 | -42 | 9 | 22 |
| 31 Dec 19 | 0 | -33 | 9 | 24 |
| 30 Sep 19 | 0 | -24 | 9 | 26 |
| 30 Jun 19 | 0 | -22 | 9 | 26 |
| 31 Mar 19 | 0 | -21 | 9 | 24 |
| 31 Dec 18 | 0 | -23 | 9 | 21 |
| 30 Sep 18 | 0 | -31 | 9 | 18 |
| 30 Jun 18 | 0 | -31 | 9 | 18 |
| 31 Mar 18 | 0 | -31 | 8 | 18 |
| 31 Dec 17 | 0 | -30 | 10 | 21 |
| 30 Sep 17 | 0 | -29 | 8 | 21 |
| 30 Jun 17 | 0 | -30 | 8 | 20 |
| 31 Mar 17 | 0 | -30 | 7 | 22 |
| 31 Dec 16 | 0 | -26 | 4 | 20 |
| 30 Sep 16 | 0 | -23 | 4 | 19 |
| 30 Jun 16 | 0 | -19 | 3 | 15 |
| 31 Mar 16 | 0 | -14 | 2 | 12 |
| 31 Dec 15 | 0 | -12 | 2 | 10 |
Quality Earnings: 5MC is currently unprofitable.
Growing Profit Margin: 5MC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 5MC is unprofitable, and losses have increased over the past 5 years at a rate of 23.6% per year.
Accelerating Growth: Unable to compare 5MC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 5MC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: 5MC has a negative Return on Equity (-112.66%), as it is currently unprofitable.